Skip to main content

Table 1 Costs of treatment for anemia of chronic kidney disease, by disease stage, prior to SEB introduction

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Treatment strategies for anemia of CKD by disease stage Drug cost per defined daily dose ($) Average dose per week Treatment cost per patient per week ($) Annual treatment cost per patient ($)
Stage III/IV short acting ESA (SC) 14.25 4,186 IU 59.65 3,101.83
Stage III/IV long acting ESA (SC) 13.36 21 mcg 62.05 3,226.59
Stage V short acting ESA (SC) 14.25 8,033 IU 114.47 5,952.45
Stage V long acting ESA (SC) 13.36 27 mcg 79.27 4,122.01
Stage V short acting ESA (IV) 14.25 11,475 IU 163.52 8,502.98
Stage V long acting ESA (IV) 13.36 38 mcg 113.71 5,912.84
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous; IU = international units; mcg = micrograms.